Table 3.
Head-to-Head Comparison Between GLP-1RAs and SGLT-2i on Different Outcomes, Evaluated in Randomized Controlled Trials (RCTs) and Real-World Studies (RWS)
| Outcomes | RCTs | RWS | Possible Reason Explaining Differences |
|---|---|---|---|
| Hba1c | Sema 1.0 mg s.c. > Cana 300mg51 | No RWS | - Up-titration of Lira in RWS is lower than RCTs - Higher discontinuation GLP-1RA vs Cana in RWS |
| (Oral Sema 14mg > Empa 25 mg) | No RWS | ||
| Lira > SGLT-2i (NWMA)52 | Lira = Empa54 | ||
| Long-Acting GLP-1RAs > SGLT-2i (NWMA)32 | GLP-1RA (Lira and exeOW) > Dapa53 GLP-1RA = Cana 30055,56 |
||
| Body Weight | Sema 1.0 mg s.c. > Cana 30051 | No RWS | |
| (Oral Sema 14mg = Empa 25 mg) | No RWS | ||
| Lira 1.2 mg < Cana 300 mg (NWMA)52 | Lira = Empa54 | ||
| Long-Acting GLP-1RAs > SGLT-2i (NWMA)32 | GLP-1RA (Lira and exeOW) = Dapa53 GLP-1RA = Cana 300mg55,56 |
Note: The symbol “>” or “<” are used to describe significant higher or lower efficacy or effectiveness between compounds.
Abbreviations: Lira, liraglutide; Sema, semaglutide; ExeOW, exenatide-once-weekly; ExeBID, exenatide-bis-in-die; Cana, canagliflozin; Dapa, dapagliflozin; NWMA, network meta-analyses.